This clinical trial is focused on young women and teenagers with certain types of cancer, including breast cancer, acute leukemia, lymphomas (both Hodgkin and non-Hodgkin), and sarcomas (such as osteosarcoma, soft tissue sarcoma, and Ewing sarcoma). The study is investigating the use of a treatment called GnRHa (Gonadotropin-Releasing Hormone agonist) during chemotherapy. The purpose of the study is to explore whether GnRHa can help protect fertility in these patients by looking at changes in the ovarian reserve, which is a measure of a woman’s remaining egg supply, after chemotherapy.
Participants in the study will receive either the GnRHa treatment or a placebo, which is a substance with no active medication. The GnRHa treatment being studied is called Pamorelin, which is given as an injection. There are two different doses of Pamorelin being used in the study: 3.75 mg and 11.25 mg. The study will follow participants for several years to monitor their ovarian reserve and other health factors. This includes measuring levels of a hormone called Anti-Müllerian Hormone (AMH), which helps indicate the number of eggs left in the ovaries, at various points after the end of chemotherapy.
Throughout the study, participants will have regular check-ups to assess their ovarian reserve and overall health. This will involve tests like ultrasounds and blood tests to measure hormone levels. The study aims to provide valuable information on how GnRHa might help preserve fertility in young women and teenagers undergoing cancer treatment. By understanding the effects of this treatment, researchers hope to improve future care for patients facing similar challenges.



Sweden